Toxoplasma immunoglobulin E (IgE) antibodies were evaluated in an immunosorbent agglutination assay (ISAGA) and an enzyme-linked immunosorbent assay (ELISA) to determine their usefulness in the diagnosis of acute infection with Toxoplasma gondii. IgE antibodies were not detected in serum specimens from otherwise seronegative individuals, individuals with chronic toxoplasma infection, or infants without congenital toxoplasmosis. In contrast, they were detected in pregnant women who seroconverted during gestation (100% by ELISA, 63% by ISAGA), patients with toxoplasmic lymphadenopathy (96% by ELISA, 88% by ISAGA), infants with signs of congenital toxoplasmosis which prompted serologic testing in the postnatal period (92% by ELISA, 67% by ISAGA), children and adults with toxoplasmic chorioretinitis (36% by ELISA, 18% by ISAGA), and adult patients with AIDS and toxoplasmic encephalitis (33% by ELISA, 25% by ISAGA). In many of the serum specimens, the titer of IgE antibodies detected by the ISAGA were close to or at the positive cutoff value. The duration of detectable IgE antibodies in patients with acute infections varied considerably among individuals but showed a trend toward a briefer duration by the ISAGA than by the ELISA. These results reveal that recrudescence of IgE antibodies in patients with reactivated chronic infection (toxoplasmic chorioretinitis and toxoplasmic encephalitis) may be useful diagnostically and that demonstration of toxoplasma IgE antibodies is a useful adjunct to currently available serologic tests for the diagnosis of acute toxoplasma infection and toxoplasmosis.
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Although the definitive diagnosis of toxoplasma infection and toxoplasmosis is established by demonstration of the tachyzoite form of the parasite either histologically or by isolation procedures, improvements in serologic diagnosis now usually obviate the need for biopsy and isolation studies, except in some patients with congenital toxoplasma infection and when disease occurs in immunocompromised patients. We and others have previously reported on the use of specific immunoglobulin M (IgM) (6, 9) , IgA (4, 11, 16) , and low-avidity IgG (8) antibodies and the differential agglutination (AC/HS) test (3, 17, 18) for the serologic diagnosis of acute toxoplasma infection during pregnancy, toxoplasmic lymphadenopathy, congenital toxoplasma infection, and toxoplasmic encephalitis (TE). A frequent clinical problem associated with many of these serologic tests is the persistence of toxoplasma IgM (2, 5, 19) and IgA (19) antibodies for months or even more than 1 year after the acute infection. For this reason and because of the variation in individual serologic responses to toxoplasma infection and toxoplasmosis, there has been a continued search for and development of serologic techniques that are both sensitive and specific and that will allow clinicians to appropriately date the approximate time that the infection was acquired.
Pinon et al. (10, 12) and Poirriez et al. (13) reported the presence of specific IgE antibodies in patients with acute toxoplasma infection, congenital toxoplasmosis, or toxo-* Corresponding author. plasmic chorioretinitis using enzyme-linked immunofiltration assays (10, 13) and immunosorbent agglutination (IgE) assays (ISAGAs) (12) . Because of their promising results, we developed an IgE ISAGA and IgE enzyme-linked immunosorbent assay (IgE ELISA) and examined these methods for testing sera from patients with a variety of clinical manifestations associated with toxoplasma infection.
MATERIALS AND METHODS Serum samples. Serum samples were obtained from 10 groups of patients as follows. Group A (n = 42 serum specimens) consisted of eight women who seroconverted during the first and second trimesters of pregnancy (14) . The last negative serum sample prior to seroconversion is referred to as the preconversion sample. The serum sample in which seroconversion was documented is referred to as the seroconversion sample. The time interval between the preconversion and the seroconversion samples was rounded off to the nearest week and was less than 8 weeks for each of the patients. Group B consisted of 17 patients (average age, 34 years; range, 17 to 69 years) with toxoplasmic lymphadenopathy diagnosed histologically by lymph node biopsy and whose serum samples were obtained within 12 weeks of onset of clinical illness (7) . Group (14) . Group F consisted of six clinically normal uninfected infants born to mothers who had serologic test results that suggested that they acquired acute Toxoplasma gondii infection during pregnancy. Serum samples from these infants were obtained within 8 weeks of birth (14) . These infants were followed clinically and serologically (by the dye test, IgM ISAGA, and IgA ELISA) for at least 6 months, had no clinical evidence of congenital toxoplasmosis, and had falling dye test titers. Group G consisted of 10 random infants without clinical or serologic evidence of congenital toxoplasmosis whose serum specimens were sent to our laboratory for routine screening. Sera from six of these infants were positive in the dye test (range, 10 to 150 IU/ml). Sera from the other four infants were negative in the dye test. Each of these sera was also negative in the IgM ISAGA (6) and IgA ELISA (16) . Group H consisted of 15 adults without clinical disease who were known to be positive for toxoplasma antibodies for more than 2 years before serum samples were drawn for the present study. Group I consisted of 33 random asymptomatic pregnant patients whose serum samples were sent to our laboratory for antenatal screening. Each of these serum specimens was positive in the dye test (titer range, 5 to 150 IU/ml) and negative in the IgM ELISA and IgA ELISA. Group J consisted of 24 asymptomatic seronegative pregnant patients sent to our laboratory for antenatal screening. Each of the serum specimens from patients in the group was negative in the dye test (less than 5 IU/ml) and IgM ELISA. In our laboratory, IgA This MAb was used at a concentration of 2.2 ,ug/ml to coat the wells for both the IgE ISAGA and the IgE ELISA. This concentration was determined in pilot experiments to be optimal; it was also the concentration that was recommended by the manufacturer.
Toxoplasma antigen preparation. Antigen for the IgE ISAGA was a suspension of formalinized tachyzoites which were prepared in the laboratory of one of us (P.T.) as described previously (6) . Antigen for the IgE ELISA was prepared from T. gondii tachyzoites of the RH strain as described previously (9), with minor modifications. Briefly, peritoneal fluid was obtained from outbred Swiss Webster mice (Simonsen Laboratories, Gilroy, Calif.) infected intraperitoneally 2 days earlier with the RH strain. The peritoneal fluid was collected in cold (4°C) phosphate-buffered saline (PBS; pH 7.2) containing heparin (10 U/ml), and the mixture was filtered through a polycarbonate membrane (pore size, 3 mm; Nuclepore Corp., Pleasanton, Calif.). The tachyzoite suspension was centrifuged at 850 x g for 30 min; the supernatant was removed and used as the source of antigen. The protein concentration of the supernatant was determined by the Lowry method (BCA protein assay reagent; Pierce, Rockford, Ill.), and antigen was used at a concentration of approximately 0.8 mg/ml. The optimal concentration of the initial lot of antigen was determined by preliminary testing, and subsequent lots of antigen were titrated to ensure reproducibility of results. Pilot experiments in which a sonicate of T. gondii was used as the source of antigen revealed poor reproducibility of results.
IgE ELISA. F(ab)2' fragments of the IgG fraction of rabbit antiserum to T. gondii were prepared as described previously (1). These fragments, at a protein concentration of 1.25 mg/ml, were conjugated to alkaline phosphatase (1). The optimal dilution of conjugate was determined in preliminary experiments and was 1:2,000. This enzyme conjugate was also used for the IgM ELISA (15) and the IgA ELISA (16).
The IgE ELISA was adapted from the ELISAs used in our laboratory for the detection of IgM and IgA antibodies (15, 16) . In brief, flat-bottom 96-well microtiter plates (Nunc, Roskilde, Denmark) were coated with 100 ,l of an antihuman IgE MAb diluted to 2.2 ,ug/ml in 0.1 M carbonate buffer (pH 9.8). After overnight incubation at 4°C, the plates were washed three times with PBS containing 0.05% Tween 20 (PBS-T; Sigma Chemical, St. Louis, Mo.) and were postcoated with 1% bovine serum albumin (BSA; Sigma) in 0.1 M carbonate buffer (pH 9.8) for 2 h at 37°C. After three washes with PBS-T, the plates were used immediately or were stored in an airtight wrap at -20°C. Each serum sample was diluted in 1% BSA in PBS-T. Sera from infants less than 6 months of age were used at a dilution of 1:10; all other sera VOL. 31, 1993 on October 28, 2017 by guest http://jcm.asm.org/ Downloaded from were used at a dilution of 1:20. Dilutions were chosen from results of pilot experiments with sera from infants and adults. Each diluted serum sample was added in a volume of 100 ,ul into four wells. A positive control serum sample with a high level of toxoplasma IgE antibodies and five control serum samples (dye test negative) were each placed in three wells on each ELISA plate. Four of the negative control serum specimens consisted of four individual serum specimens from four individual patients. The fifth control serum specimen was a pool of serum specimens from three other individuals. After 2.5 h of incubation at 37°C, the wells were washed three times with PBS-T. Antigen was added in a volume of 100 RI into three of the wells for each serum sample, and the plates were incubated at 4°C for 18 h. Diluent without antigen was added to the fourth well for each serum sample. The antigen-free well of each set of wells for the serum sample served as the internal standard, to control for nonspecific IgE binding to the conjugate. If there was nonspecific IgE binding to the conjugate, the test was repeated. Pilot experiments determined that the positive and negative control sera did not bind nonspecifically to the conjugate. Thus, antigen-free wells were not required for the control sera. After washing the wells three times with PBS-T, 100 pul of alkaline phosphatase-conjugated rabbit anti-toxoplasma F(ab)2' at a dilution of 1:2,000 was added. After 3 h of incubation at room temperature, wells were washed three times with PBS-T. b The results of the IgE ELISA were expressed as the number of SDs above the negative controls.
controls plus 5 SDs. Serum from each of the infants had positive dye test titers, ranging from 150 to 1,200 IU/ml. Sera from all infants were positive in the IgM ISAGA and/or IgM ELISA. IgA antibodies were detectable in the sera from all the infants. Sera from the mothers of 11 of these infants were obtained within 1 month of the time that corresponding samples were obtained from the infants. Each was positive in the IgE ELISA and 10 were positive in the IgE ISAGA (data not shown). Of interest is the serologic response in one of these mothers, who gave birth to two symptomatic twins (patients 2 and 3); the parasite was isolated from both of the infants. Her serum sample was positive in the IgE ELISA at an absorbance value between the negative pool plus 3 SDs and the negative pool plus 4 SDs and was negative in the IgE ISAGA. Sera from both of her children had IgE ELISA absorbance values of greater than the negative pool plus 5 SDs and were negative in the IgE ISAGA. These data further support our conclusion and that of Pinon et al. (12) that the IgE antibody responses in the infants were specific and not the result of maternal transfer.
Uninfected infants born to mothers with serologic evidence of acute infection during gestation (group F). The six infants who did not have clinical or serologic evidence of congenital toxoplasmosis (group F) were born to mothers who had serologic evidence of acute infection that was most likely acquired during pregnancy. IgE antibodies were not detected by ISAGA in the sera from any of these infants. Sera from four of the infants were also negative by the ELISA (Table 3 ). For serum from patient A, the IgE ELISA result was equivocal and all subsequent serum samples were negative. For serum from patient F, IgE antibodies were detected at 1 and 5 weeks of age. At 1 year of age, both of these infants (patients A and F) remained without clinical evidence of congenital toxoplasmosis, despite extensive investigations. They had received antitoxoplasma therapy for only 1 month. They continue to be under close follow-up by their respective physicians.
DISCUSSION
The purpose of the present study was to determine the value of demonstrating toxoplasma IgE antibodies in the sera of patients with different clinical problems associated with T. gondii infection. Seronegative individuals, asymptomatic individuals who were chronically infected with T. gondii, and infants without congenital toxoplasmosis (except for one infant in whom we considered it a false-positive result) did not Detection of toxoplasma IgE antibodies for the diagnosis of acute toxoplasma infection (seroconversion during pregnancy and toxoplasmic lymphadenopathy) and for congenital toxoplasma infection serves as a useful adjunct to currently available tests. Detection of IgE toxoplasma antibodies also appears to be associated with reactivated chronic (latent) infection and may be important for the diagnosis of these conditions.
